Kiniksa Pharmaceuticals International, plc (KNSA) Stock Price & Analysis
Kiniksa Pharmaceuticals International, plc (KNSA) closed at USD 80.79 on Thursday, October 22, 2026, up 1.37% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 79.7; the Oct 22, 2026 session ranged USD 78.39–81.28 on volume of 429,625 shares. Market capitalization is $6.30B, with a 52-week range of USD 35.2–84.06 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/KNSA.md
Key facts (KNSA)
- Last four reported quarters (through Jun 30, 2026): revenue $841M, net income $80.7M (9.6% margin), free cash flow $183M (SEC filings).
- Valuation: P/E 78.2x (avg 72.4x at the last 2 fiscal year-ends).
- Analysts: Buy (mean 1.88 on a 1–5 scale) (8 analysts), mean target USD 98 (range 87–108).
- Total return with dividends: 1Y +108.4% vs S&P 500 +14.9%; 5Y +653.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 0.32, revenue estimate $260M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (KNSA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $38.5M | $220M | $270M | $423M | $678M | $841M |
| Gross profit | $29.4M | $197M | $237M | $362M | $600M | — |
| Operating income | -$157M | $9.8M | -$25.2M | -$45.6M | $77.2M | $100M |
| Net income | -$158M | $183M | $14.1M | -$43.2M | $59.0M | $80.7M |
| EPS (diluted) | -$2.30 | $2.60 | $0.20 | -$0.60 | $0.75 | — |
| Free cash flow | -$127M | $5.7M | $13.2M | $25.4M | $136M | $183M |
| Gross margin | 76.4% | 89.6% | 87.6% | 85.6% | 88.5% | — |
| Operating margin | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% | 11.9% |
| Net margin | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% | 9.6% |
| Revenue growth | — | +471.2% | +22.7% | +56.6% | +60.1% | — |
| Cash + short-term investments | $182M | $191M | $206M | $244M | $414M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (KNSA)
P/E 78.2x · P/S 7.5x · P/FCF 34.5x · P/B 9.6x · FCF yield 2.90% · Earnings yield 1.28%
P/E at fiscal year-ends: Dec 2025 55.2x, Dec 2023 89.6x.
Analysts (KNSA)
Consensus Buy (mean 1.88 on a 1–5 scale), 8 analysts; mean target USD 98 (low 87, high 108).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-30 | Goldman Sachs | Target raised | Buy | $75 → $90 |
| 2026-07-29 | JP Morgan | Target raised | Overweight | $72 → $107 |
| 2026-07-29 | Canaccord Genuity | Target raised | Buy | $64 → $98 |
| 2026-07-29 | Wedbush | Target raised | Outperform | $72 → $99 |
| 2026-07-29 | Citigroup | Target raised | Buy | $60 → $100 |
| 2026-07-23 | Goldman Sachs | Target raised | Buy | $60 → $75 |
| 2026-07-13 | Wells Fargo | Target raised | Overweight | $57 → $74 |
| 2026-06-29 | Wedbush | Target raised | Outperform | $59 → $72 |
Total return (dividends reinvested) (KNSA)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +108.4% | +653.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +108.9% | +49.6% |
| Volatility (annualized) | 47.5% | 50.6% |
| Max drawdown | -21.1% (May 2026→Jun 2026) | -45.7% (Nov 2021→May 2022) |
KNSA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.32 | $0.31 | +2.4% | $260.2M | 4 |
| Next quarter (ends Dec 2026) | $0.29 | $0.29 | -2.5% | $276.2M | 4 |
| Current fiscal year (ends Dec 2026) | $1.16 | $1.16 | -0.2% | $994.4M | 4 |
| Next fiscal year (ends Dec 2027) | $1.62 | $1.70 | -5.0% | $1.22B | 4 |
KNSA options: expected move
Options price a move of about ±12.0% (±$9.70) by Nov 20, 2026, which includes earnings on Oct 27, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 53.0% | ±12.0% |
| Dec 18, 2026 | 56 | 49.2% | ±15.4% |
| Jan 15, 2027 | 84 | 56.7% | ±21.7% |
| Apr 16, 2027 | 175 | 52.9% | ±28.8% |
30-day implied volatility 52.6% vs 28.4% realized over the last 30 trading days. Put/call ratio (volume) 0.06. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 80.79 |
|---|---|
| Change | ▲ 1.37% (up) |
| Previous Close | USD 79.7 |
| Open | USD 79.32 |
| Day Range | USD 78.39 – 81.28 |
| 52-Week Range | USD 35.2 – 84.06 |
| Volume | 429,625 shares |
| Market Cap | $6.30B |
| Exchange | NMS |
Technical Analysis (KNSA)
Nexqual's technical model rates KNSA "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.55 (neutral) |
| vs SMA50 | Above (USD 78.13) |
| MACD | 1.05 (positive) |
Analyst Ratings (KNSA)
Wall Street analysts rate KNSA "Buy" based on 8 analysts, with a mean price target of USD 98 (range USD 87–108), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 98 |
| High Target | USD 108 |
| Low Target | USD 87 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (KNSA)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD 0.32 |
| Revenue Estimate | $260.16M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.3 vs est 0.29 ▲ beat |
| 2026-03-31 | USD 0.27 vs est 0.16 ▲ beat |
| 2025-12-31 | USD 0.17 vs est 0.4 ▼ miss |
| 2025-09-30 | USD 0.23 vs est 0.37 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (KNSA)
| Total Revenue | $840.85M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +55.40% |
| Gross Margin | +54.50% |
| Operating Margin | +11.16% |
| Profit Margin | +9.59% |
| ROE | +14.04% |
| Debt / Equity | 0.01 |
| Current Ratio | 3.9 |
| Total Cash | $525.93M |
| Total Debt | $8.90M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $182.84M (21.7% of revenue) |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (KNSA)
Nexqual rates Kiniksa Pharmaceuticals International, plc's overall financial health "Strong" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Strong — Revenue +60% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 11% (last 12 months) |
| Balance Sheet | Strong — $526M cash vs $9M debt, net cash position |
| Cash Flow | Strong — FCF $183M (last 4 quarters to Jun 2026, SEC), 22% margin |
| Efficiency | Mixed — ROE 14%, ROA 8.0% |
Ownership (KNSA)
| Insider Ownership | +3.51% |
|---|---|
| Institutional Ownership | +101.72% |
| Shares Outstanding | 48.29M |
| Float | 39.86M |
| Short % of Float | +9.45% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (KNSA)
Kiniksa Pharmaceuticals International, plc is led by Sanjiv K. Patel, CEO & Chairman of the Board, per Nexqual as of October 23, 2026 at 10:11 UTC.
| CEO & Chairman of the Board | Sanjiv K. Patel |
|---|---|
| Executive VP & CFO | Mark A. Ragosa C.F.A. |
| Executive VP, COO & Principal Operating Officer | Ross Michael Moat |
Major Backers & Investors (KNSA)
Notable institutional backers of Kiniksa Pharmaceuticals International, plc include FMR, LLC, Rubric Capital Management LP, Fidelity, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 17.3% |
| Rubric Capital Management LP | 9.92% |
| Fidelity | 9.44% |
| Baker Bros. Advisors, LP | 7.03% |
| Tang Capital Management, LLC | 5.61% |
| Morgan Stanley | 2.51% |
| Arrowstreet Capital, Limited Partnership | 2.38% |
| Spruce Street Capital LP | 2.28% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.12% |
| BlackRock | 6.8% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LNTH | Lantheus Holdings, Inc. | USD 100.1 | ▼ 0.14% |
| HIMS | Hims & Hers Health, Inc. | USD 29.13 | ▼ 0.27% |
| AMRX | Amneal Pharmaceuticals, Inc. | USD 20.48 | ▲ 1.39% |
| ALKS | Alkermes plc | USD 44.18 | ▲ 1.61% |
| RGC | Regencell Bioscience Holdings L | USD 9.81 | ▼ 9.17% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 35.33 | ▲ 1.55% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt